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Background: Appropriate use of inhaled therapies for asthma and chronic obstructive pulmonary disease
(COPD) is critical to ensuring good patient outcomes, efficient use of healthcare resources and limiting the
effects of high-morbidity. The appropriate choice of inhaler and active therapy, incorporating patient
preferences, can help improve treatment adherence and long-term outcomes. Despite this, many current
inhalers are non-intuitive to use, and require extensive training.
Methods: In this review, an expert panel considers the evidence for the use of inhaler devices in management
of COPD and asthma. The panel also evaluates the value of innovation in inhaler technologies, which
optimise the use of existing molecules from a clinical, economic and societal perspective.
Conclusions: The panel conclusion is that there remains a substantial unmet need in inhaler technology and
that innovation in inhaler devices can provide real-world health benefits to patients. Furthermore, we
recommend that these innovations should be supported by healthcare systems through appropriate pricing
and reimbursement mechanisms.
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C
hronic respiratory diseases, such as asthma and
chronic obstructive pulmonary disease (COPD),
are responsible for more than 150,000 deaths in
the European Union (EU) every year and affect over
60 million more (1). This clinical impact is reflected in
the economic burden of these diseases in the EU, with the
combined annual cost of care and productivity losses
amounting to EUR33.9 billion and EUR48.4 billion for
asthma and COPD, respectively (2013) (1). Against this
backdrop of high morbidity, mortality, and economic
burden, the goals of treatment in asthma and COPD are to
optimise disease control, with limited flare-ups and rare
occurrence of severe exacerbations (2, 3). Although oral,
injectable, and inhaled products are available, inhaled
therapy is preferred because of the high drug concentra-
tion which can be achieved locally within the lungs, with
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reduced risk of systemic side effects (4). However, good-
quality outcomes with inhaled therapy hinge upon the
appropriate use by patients (4). A range of inhalers are avail-
able to deliver therapy, each of which is associated with
benefits and drawbacks. In general, inhalers can be divi-
ded into two categories: pressurised metered dose inhalers
(pMDI) and dry powder inhalers (DPI). Within and
between these categories the inhalers differ in effectiveness
of drug delivery and ease of use (5).
Global clinical guidelines issued by the Global In-
itiative for Asthma (GINA) and the Global Initiative for
Chronic Obstructive Lung Disease (GOLD) recommend
that persistent, moderate-to-severe asthma and COPD at
high risk of exacerbations be treated with a combination
therapy of inhaled corticosteroid (ICS) and long-acting
beta-agonist (LABA), administered via an inhaler. The
guidelines also recognise that this therapy is best admi-
nistered in a fixed-dose combination (FDC) from a single
inhaler, rather than from two separate inhalers (2, 3).
This is demonstrated by reduced adherence and increased
discontinuation rates in patients using multiple inhalers
versus those using FDC devices (6).
Choosing the appropriate molecule combination and the
inhaler are important determinants of treatment outcomes.
This choice relies upon matching the needs of a particular
patient to the benefits of a particular inhalation device. In
addition to considering a patient’s disease stage, the choice
of treatment should also be influenced by the patient’s
ability to administer the prescribed dose effectively and the
device preferences. This is important, because misuse of
inhalers will have a significant negative impact on disease
control (7, 8). As the dose delivered to the lungs is highly
dependent on the correct use of the delivery system, the
European Respiratory Society recommends that those
who prescribe inhalers should ensure that patients use
their therapy correctly (5). This is particularly important
as training patients on the correct use of many existing
inhaler devices can be difficult, leading to errors and low
patient satisfaction.
The availability of novel inhalers has been facilitated by
the loss of exclusivity rights for several of the molecules
that form the basis of inhaled therapy for asthma and
COPD. However, national healthcare systems in several
countries (e.g., Germany, Austria, Belgium, Poland,
Romania, Slovakia, Hungary, and Lithuania) do not
recognise the value of innovation in new inhalers through
their pricing and reimbursement decisions, which may
result in restricted availability of innovative inhalers in
these countries. The lack of access limits the options to
optimise patient care, and may discourage further invest-
ment in inhaler development.
In this paper, we examine some of the key benefits
of inhaler innovation that support the rationale for
investment in improved inhaler devices. This expert panel
review of the available evidence postulates that the value
of clinically meaningful innovation in inhalers, with off-
patent molecules, should be recognised through pricing
and reimbursement decisions. This innovation must deliver
real-world health benefits to patients, which must address
clinically relevant unmet needs.
Methodology
A wide range of literature has been published on the
effect and impact of innovations in asthma and COPD
and establishes the role of appropriate, well-used inhaled
therapies. In order to fully understand the complex fea-
tures of the treatment of asthma and COPD, a two-stage
process was adopted.
Semi-structured literature review
In the initial stage, a semi-structured literature review was
conducted to understand the scope and issues associa-
ted with various aspects of asthma and COPD therapy.
Broad search terms were applied to establish a full review
of the (English language) literature using PubMed. The
terms used were asthma, COPD, adherence, compliance,
persistence, patient, preference, choice, economics, social,
and outcome. A rapid review was conducted to remove
all references not related directly to inhaled therapies for
asthma and/or COPD, duplicate references/corrections,
publications on highly specific/atypical patient popula-
tions, and commentary publications on other studies. A
final shortlist of 428 papers was used to create materials
taken forward to the Delphi panel review. These materials
summarised the 428 papers into seven critical dimensions
as follows: current unmet needs, patient compliance and
adherence, patient preference, choice and outcomes,
safety and pharmacovigilance, access to innovation, and
economic impact of innovation. Within each dimension,
four or five proof points were developed to present key
supporting evidence.
Delphi panel review
A face-to-face panel was convened consisting of eight
experts from diverse backgrounds (clinical, economic,
and social) and a number of different EU countries. The
goals of the panel were to objectively assess the existing
evidence regarding inhaler innovation. All experts that
participated in the face-to-face panel are the authors of
this review.
Over 2 days, the panel was presented with the summary
statements for each of the seven critical dimensions iden-
tified during the semi-structured literature review. The
panel discussed each summary statement and support-
ing proof points in detail. Subsequently, an anonymous
Delphi evaluation (9) was conducted using the following
approach: for each summary statement, the panel was
presented with a short overview of the evidence base and
asked to comment anonymously on the summary state-
ments and proof points (in terms of language, importance,
and strength of supporting data) and to recommend,
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again anonymously, enhancements to the data set and the
summary of the data.
For each summary statement, the anonymous feed-
back was aggregated and fed back; subsequently, one to
four rounds of anonymous feedback and iteration were
completed to establish a consensus on the best summary
of the evidence provided. This consensus has provided the
expert perspectives used throughout this review. Sections
within the perspectives section reflect the consensus
summary statements agreed by the panel.
Perspectives of the expert panel
Current inhalers are often poorly used, are
not intuitive, and require extensive training
Current pMDI and DPI inhalers require a complex
administration procedure involving several steps (dose
loading, inhaler priming, and breathing management) in
order to ensure maximal benefit of the medication. These
steps require that patients display great dexterity and
coordination (10). Failure to follow the instructions may
lead to inhalation errors, some of which reduce, or prevent
entirely, deposition of the medication in the lungs (11).
In a videotaped study using a validated scoring technique,
40% of COPD patients demonstrated at least one error in
technique (12).
In addition to problems in achieving correct inhalation
technique among the general patient population, several
specific groups have particular problems using existing
inhalers. This leads to certain patients, such as those with
low inspiratory flow rate, poor cognitive ability (13),
arthritis, and the elderly, having difficulty achieving ade-
quate dosing (14, 15). Incorrect inhalation technique is
particularly common among older people and those with
reduced inspiratory flow rate (15). Indeed, most patients
with COPD are unable to use a pMDI or DPI correctly.
Common errors include inadequate coordination of ins-
piration and actuation, and inability to achieve a suffi-
cient inspiratory flow rate (15).
Complicating this situation is the fact that the capacity
for physicians and nurses to train the patient is often
limited. Both time constraints and inadequate knowledge
among healthcare professionals (HCP) can lead to in-
effective patient education. In a review of 20 relevant
studies, only 28% of doctors and 22% of nurses were able
to describe or perform all the critical steps for using in-
halers (16). Many patients do not receive inhaler training
of any kind, with one study showing 25% of patients
report having never received verbal instruction on correct
inhalation technique (17).
Poor training, coupled with complex procedures for
use, mean that 5090% of asthma patients show incorrect
technique in clinical studies (18).
Even when patients are able to demonstrate correct
inhaler technique during consultation with an HCP, they
may not maintain this standard at other times (19, 20).
Although retraining on inhaler technique can help some
patients, 6578% of patients who show poor technique on
pMDIs do not improve with subsequent training (21).
Difficulties of using current inhalers can negatively
impact patient outcomes through patients
displaying poor inhalation technique
The frequently cumbersome nature of existing inhalers
makes patient education and disease management more
complex and reduces healthcare efficiency (4). Correct
use of inhalers is critical to ensuring that patients receive
their prescribed medication doses. In a recent survey, 66%
of expert physicians cite ‘failure to master device’ as a
primary reason for lack of efficacy in respiratory disease
(22). This belief is supported by real-world observations
of both reduced lung deposition of the active ingredient
and worsening of asthma control as the number of mistakes
in inhaler technique increases (23). Failure to use inhalers
correctly can significantly impact disease management
(2, 24).
Poor inhalation technique, as measured by the occur-
rence of critical inhaler errors, has been shown to signi-
ficantly reduce the degree to which asthma and COPD
are controlled, to impact patient health-related quality of
life (HRQoL), and to increase the risk of unscheduled
healthcare resources being required for disease manage-
ment. Melani and colleagues found that patients making
critical inhaler errors were at significantly higher risk of
suffering limitations in everyday life, shortness of breath,
use of reliever inhalers, uncontrolled disease, and sleep
disturbance (pB0.009). Furthermore, the occurrence of
critical inhaler errors also led to significant increases in
the risk of requiring hospitalisation, visiting the emer-
gency departments, requiring antibiotics, and using a
course of oral corticosteroids (25).
In a second study, asthma stability, as measured by
the asthma instability index score (AIS), has been found
to be impacted by poor inhaler use in France. AIS and
evaluation of inhalation technique data were available
in 3,709 asthma patients (out of a total evaluable popu-
lation of 3,955) and showed that people who did not use
their inhalers correctly recorded significantly higher AIS
scores (7).
Incorrect use of inhalers, including under- and over-
dosing driven by patient error, can also impact safety
and tolerability (25). Inappropriate patient use has also
been cited as a primary contributing factor in adverse
events (25).
Choice of inhaler, taking patient preference into
account, can support optimal disease control
In addition to the impact on critical errors, inhaler com-
plexity, confidence in efficacy, and the need for frequent
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retraining can influence patient preference for specific
inhalers. Consequently, many patients express preferences
for certain devices, and those who are able to use their
inhaler efficiently are more likely to express a preference
for the inhaler they currently use (2629). Patients’ per-
ceived satisfaction with their inhalers in asthma correlates
with improved disease control and treatment adherence
(29). Patients have expressed a preference for an inhaler
that is small, with an ergonomic mouthpiece and an easy
to use dose preparation mechanism, and providing enough
medicine for at least a month of treatment (30).
It has been shown that increases in adherence, quality
of life, and disease control (including exacerbations and
hospitalisations) are directly linked to patients’ satisfac-
tion with their inhaler device (2831). Conversely, poor
patient preference, coupled with the complexity of inhaler
use and the implied critical errors, adversely impacts
adherence to the prescribed regimen (29).
In addition to real-world evidence that effectiveness
can be maximised by using a patient-preferred inhaler,
a critical element at the heart of choice of therapy is the
maintenance of patient safety. This is particularly im-
portant for inhaled medicines, where the complexities
of getting the right amount of drug to the lungs
can impact the riskbenefit profile of the drugdevice
combination (32).
Finally, patient preference can also drive healthcare re-
source benefits. Several cross-sectional studies have shown
that, even if the inhaler is more expensive than standard
inhalers, selecting an inhaler based on the patient’s pre-
ference can be cost-effective (27). In one study in which 100
patients were randomised across seven different devices, it
was demonstrated that using a patient-preferred inhaler
could save 14% of total costs associated with asthma (27).
A greater range of treatment options in inhalers brings
opportunities for tailoring healthcare to individual patient
needs, through physician/patient dialogue. Offering patients
and providers choice also helps to create competition,
encouraging efficiency and responsiveness to patients’
preferences and healthcare needs.
Poor adherence to asthma and COPD treatments
is associated with an increased number of
exacerbations, hospital admissions, and deaths
For inhaled therapy in chronic lung disease, non-optimal
usage can take two forms; firstly, patients can fail to
initiate treatment which can be related to the ease of use
of a particular inhaler. Secondly, the patient can fail to
follow their treatment regimen as prescribed, for example,
by missing scheduled doses or by stopping treatment
after a period of time. Even after accounting for the
context of chronic diseases, where adherence rates are
typically between 60 and 80%, poor adherence has
been observed in respiratory disease (33). On average,
adherence rates for asthma and COPD are approximately
5060% (34).
Real-world evidence demonstrates that poor adherence
to asthma and COPD treatment is associated with an
increased number of exacerbations, hospital admissions
and deaths. Approximately one in four asthma exacerba-
tions are attributable to poor adherence (35). In addition,
for asthma patients on FDCs, each 25% increase in
adherence rate reduces an asthma related hospital visit by
10% and the odds of needing additional reliever therapy
(short-acting beta agonist) by 10% (36). In a study of
more than 30,000 adults, the rate of mortality linked to
asthma decreased by 21% for each additional inhaler
prescribed in the prior 12 months (demonstrating that
better compliance can reduce mortality) (37). A similar
study of over 6,000 patients demonstrated that adherence
to inhaled medication is significantly associated with re-
duced risk of death and admission to hospital due to
exacerbations in COPD (38).
Inhaler ease of use and patient satisfaction can im-
prove adherence and enhance long-term efficiency in the
use of healthcare resources (35, 36). In a real-world obser-
vational study of asthma specialists (n330), primary
care physicians (n252) and asthma patients (n2,135),
increasing patient satisfaction with inhaler correlated
with improved treatment adherence (29). Similar findings
were reported for 1,443 real-world COPD patients (39).
These data suggest that providing patients with a simple,
easy-to-use, effective inhaler, has the potential to increase
patient treatment adherence and therefore to improve
patient outcomes.
Improving treatment adherence can also reduce health-
care costs associated with the treatment of asthma and
COPD. A retrospective analysis of a claims database of
1,365 COPD patients in Spain showed that non-adherent
patients incurred higher medicine costs than adherent
patients (40).
Different inhalers have different dose-delivery
profiles and cannot be directly substituted
It is important to ensure that patients always receive
an appropriate dose of medication when they use their
inhaler. Inconsistent dosing occurs for a number of rea-
sons that can be either inhaler or user dependent. The
amount of drug delivered to the lungs depends on the
patient’s ability to use their inhaler correctly and to avoid
making inhaler errors; it also depends on the technical
characteristics of the inhaler and drug formulation (41).
Many inconsistencies in dosing occur as a result of
patient errors. In the case of pMDIs, poor coordination
and the patient’s breathing rhythm have been identified as
the main reasons for inconsistent dosing (19). Along with
the coupling of inhaler and treatment, other features of
an inhaler may also lead to inconsistent dosing. Many
inhalers require the patient to clean any excess powder
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from the inhaler mouthpiece (42). Otherwise dosing can
become inconsistent, due to dose accumulation taking
place in the mouthpiece of the inhaler (42).
Regulatory pathways have been established which ad-
dress the complexity of inhaler dose delivery mechanisms.
Inhaled products with off-patent molecules are registered
under a comprehensive and complex hybrid approval
(Article 10.3 of Directive 2001/83 EC). In order to show
therapeutic equivalence, the clinical (pharmacodynamic)
data needs to be submitted alongside the typical phar-
macokinetic data to support the application as required
by the Orally Inhaled Product (OIP) guidelines. The key
challenge is showing the therapeutic equivalence given
the inconsistency in performance of the original inhalers.
The regulatory framework in Europe, using a stepwise
approach based on both in vitro and in vivo data, recog-
nises the complexity of demonstrating equivalence (43).
Even when inhalers successfully meet the therapeu-
tic equivalence criteria set out by the regulatory bodies,
account must be taken of real-life practice, where the
inhaler can have a strong impact on efficacy for the safety
of the individual patient. A patient’s ability to use one
inhaler does not imply that they will readily and accurately
use a substitute. In a 2-year retrospective study in the UK
of 824 matched patients, the odds ratio for treatment
success was significantly lower in the switched cohort
compared with controls (pB0.001), while the odds ratio
for unsuccessful treatment was significantly higher (pB
0.001) (44). The authors acknowledge the potential for
alternative reasons for this observation but conclude that
switches in ICS device without clinical visit or consultation
were associated with worsened asthma control (44).
Real-world observational studies show that the level
of disease control that can be achieved is at least partly
driven by inhaler characteristics and not just by the drug
(28). Each inhaler has a specific routine that must be fol-
lowed and patients need to be adequately trained before a
switch may be considered (28). The benefits of choosing
an optimal inhaler first time, avoiding wastage and inef-
fective inhalation, are evident (27). Physicians and their
staff must be central to the decision to change inhaler,
while providing training and checking technique. A more
intuitive inhaler, which can be handled correctly by more
patients, may have the potential to reduce costs.
Innovative inhalers can contribute to improving
patient inhaler technique and achieving disease
control leading to better allocation of healthcare
resources
Investing in innovation in respiratory inhalers delivers eco-
nomic benefits, both directly within healthcare (through
better management of healthcare resources, fewer exa-
cerbations, and improved healthcare efficiencies) and
indirectly (through maintenance of productivity, inward
investment in skills, and long-term employment).
In 2010, the proportion of treated asthma patients
assessed as having ‘not well-controlled’ asthma was 53.5%
(45). On average, a patient with uncontrolled asthma
costs a healthcare system around four times as much as
a patient who is well controlled on therapy (46, 47). A
proportion of these costs could be avoided through
improved inhaler efficiency and technique.
A recently published economic model in the UK
suggested that, in 2013, poor inhalation technique among
the users of FDCs of ICS and LABA was substantial.
It was estimated that approximately 12% of direct un-
scheduled healthcare costs of asthma and COPD can be
attributed to poor inhalation technique (none planned
visits and treatment due to flare up) (48). Rates of acute
care episodes are 3.5 times more likely for those with three
to four control problems versus those with no control
problems (49), while improved adherence is associatedwith
reduced rates of hospitalisation and associated costs (50).
Discussion
The perspectives outlined above postulated around the
benefits that could be achieved with continuous innova-
tion in respiratory devices. There remains an unmet need
for new and innovative inhalers to address some of the
limitations of existing products. In addition, innovative
inhalers should offer attributes and features that patients
particularly value, and contain different classes and com-
binations of medicines used to treat asthma or COPD by
inhalation. Difficult-to-use inhalers can negatively impact
patient outcomes through patients displaying poor in-
halation technique which can contribute to low treatment
adherence. Evidence shows that poor inhalation techni-
que is associated with an increased risk of hospitalisa-
tions, emergency department visits, and administration
of antimicrobials or oral corticosteroids; all of which
translates into considerable cost implications while also
increasing the risk of side effects and added morbidity.
Similarly, low adherence to asthma and COPD treatments
contributes to poor patient outcomes and is associated
with considerable costs. A lack of satisfaction with exist-
ing inhalers is one of the reasons for poor asthma and
COPD treatment adherence, as evidence shows that the
more satisfied patients are with their inhalers, the more
likely they are to adhere to treatment. In that context,
patient preference for certain inhalers, or more precisely
for certain attributes and features, are important. As the
evidence reviewed here shows, patient preference can be
a good predictor of future treatment outcomes.
Taking all the above into account, there is potential
for new and more effective inhalers to reduce the overall
cost burden associated with asthma and COPD. More
patients displaying the correct technique and improved
patient adherence would ultimately lead to fewer unsched-
uled healthcare events that lead to increased costs. How-
ever, it needs to be questioned whether adherence should
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be viewed as a patient relevant outcome parameter rather
than a variable to explain treatment success. Theoretically,
it might be possible that a comparatively easy to use and
forgiving inhaler would deliver higher levels of treat-
ment success and therefore prompt patients to decrease
its use, which has been called intentional non-adherence.
Thus, the interplay between inhaler ease of use, patient
preference and satisfaction, adherence, and patient rele-
vant outcomes may be considerably more complex than
suggested by simple one-dimensional models of inhaler
features determining patient adherence and eventually
outcomes.
In the current environment, there are effective medi-
cines but ineffective delivery methods, and these are driven
by the complexity and multitude of existing inhalers
and inadequate training. Optimising the delivery device
represents a primary area of unmet need in ICS/LABA
treatments (23, 51). New inhalers need to have simple and
intuitive operation. To provide a low rate of accidental
critical errors, they must consistently deliver the correct
dose across a range of real-life situations, for example, low
inspiratory flow rate, varied inhalation-actuation timings,
and a range of inhaler orientations (52). This should be
preferably delivered in a limited number of steps required
to charge and properly use the inhaler such as a hand-
ling sequence limited to ‘exhale  open  inhale  close’
manoeuvres. In addition, the inclusion of positive feed-
back mechanisms is absent in many inhalers. These
measures enable patients to feel confident that an appro-
priate dose has been delivered, while supporting the
maintenance of correct inhaler usage (53).
Development of novel inhalers is complex, time con-
suming, and costly. This is attributable to the strict re-
quirements of the regulatory pathway for hybrid inhaler
device medicine combinations; the fact that the pro-
duction capability for such devices requires significant
investment and also the large resources required to
commercialise such medicines through investment in
physician education and the provision of training. Aside
from financial considerations, there are technological
barriers to the development of innovative new inhalers,
and only a limited number of pharmaceutical compa-
nies currently have sufficient knowledge to develop new
inhalers. This assertion is supported by the fact that,
despite genericisation of the molecules for numerous
asthma therapies (e.g., Symbicort in 2011) (54), the
costs of development and the uncertainties of access
have meant that direct alternatives containing the same
active ingredients are limited across the EU.
Patients will only be able to benefit from innovation
in inhaler devices if the pharmaceutical manufacturers
have sufficient incentives to invest in such innovations.
However, mechanisms of cost control may act to restrict
the development of improved inhaler technology. In the
context of novel inhalers with off-patent molecules, this
includes the generic approach to pricing of such medi-
cines by many healthcare systems in Europe as well as
attempts to tender them as commodities. Lack of recog-
nition of innovation in inhaler devices which deliver off-
patent molecules can, at best, prohibit patients in these
countries accessing new inhaler technology. At worst, it
can limit the financial incentives for the pharmaceutical
manufacturers to invest in the development of novel
inhalers.
There are numerous approaches to address the devel-
opment and introduction of novel inhalers, ranging from
the flexibility to combine a full portfolio of medicines
to treat asthma or COPD and to choose a conventional
pricing and reimbursement process, to the development
of a specific process for hybrid medicines with off-patent
molecules similar to the approach adopted for biosimilar
therapies.
Healthcare systems need to encourage device-led inno-
vation by allowing reimbursement decisions to reflect such
innovation. More competition in the field of inhalers will
lead to innovation in new inhaler technology and deliver
improved health outcomes.
Conclusion
Innovation in inhaler devices provides real-world health
benefits to patients by addressing clinically meaningful
unmet needs. As such, with appropriate clinical studies
addressing handling and safety issues, it should be recog-
nised through pricing and reimbursement approaches.
Access to innovative inhaler devices, at a price that
reflects the value of clinically meaningful innovation,
has the potential to bring benefits to patients, budget
holders, clinicians, and wider society.
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